Telix Pharmaceuticals
A Melbourne radiopharmaceutical company that earns almost all its money from US prostate cancer scans, now paying US$1.65B, mostly in new shares, for Germany's ITM to become a cancer therapy seller.
ITM merger announcement (6-K, Sep 21, 2026)- Revenue
- $245M in July to September 2026, up 19% on a year ago; scans made $201M of it.
- Profit
- $38M net profit in the first half of 2026, which includes a one-off $40M from Regeneron.
- Debt
- $516M of borrowings at June 30, 2026, almost all a 1.50% convertible due 2031.
- Watch
- Dec 1 shareholder vote on issuing about 105.8M shares to buy ITM.
- AI
- Small owns AI tools for reading PSMA scans, but says they are not yet used to develop its drugs.
- Hiring
- 41 of 58 open Americas postings are tagged "USA- Remote"; plant jobs are on site.
- Listings
- 43 → 45 remote listings since Oct 10.
Prostate cancer scans pay the bills.
Precision Medicine sells imaging drugs, mainly Illuccix and Gozellix for PSMA PET scans of prostate cancer. Manufacturing Solutions is mostly the RLS radiopharmacy network bought in January 2025. Therapeutics is still in trials, so it earns little.
- 1Two approved PSMA scan agents and wide US reachIlluccix and Gozellix are both FDA approved, and over 225 commercial radiopharmacies distribute Illuccix in the US. Precision Medicine revenue grew 30% in Q3 2026.FY2025 annual report (6-K, Feb 20, 2026); Q3 2026 update
- 2It owns more of its supply chain than most rivalsRLS gives it over 30 radiopharmacies in 18 states and about 1,500 customers. It also runs sites in Angleton (Texas), Sacramento, Brussels South and Yokohama.FY2025 annual report (6-K, Feb 20, 2026)
- 3Big partners pay to share its pipelineRegeneron paid a non-refundable US$40.0M in April 2026 for four joint radiopharmaceutical programs, with costs and profits split equally and options on four more.H1 2026 half-year report (6-K)
Telix Pharmaceuticals brought in $245 million in 92 days.
That is about $39 million more than the same three months a year earlier.
Revenue is not profit. It is the money that came in before Telix Pharmaceuticals pays any of its costs.
Q3 2026 update (6-K, Oct 21, 2026)Still profitable, but down from $55 million in FY2024.
Revenue more than doubled in two years. In FY2025 it kept 4 cents of every revenue dollar as operating profit.
- FY2023: kept 3¢ of every $1
- FY2024: kept 11¢ of every $1
- FY2025: kept 4¢ of every $1
Nearly all the debt is a convertible bond that can turn into shares at US$13.85, and holders can ask for repayment after three years. Buying ITM would add about US$301.8M of ITM net debt at closing.
The rest of Telix Pharmaceuticals, for members.
The fine print, who gets paid most, where it looks headed and our calls. Free for 3 days, then $9 a month.
- 03
What the filings say, and what we think it means.
10 flags, each with our read
- 05 · 06
How Telix Pharmaceuticals uses AI, and what its hiring says.
- 07
Your view of the next year, in a share price.
- 08
The signals, and which way they push.
5 signals
- 09
Where Telix Pharmaceuticals ends up, if we had to bet.
5 predictions, with odds
Read by the Still Remote research agent on November 3, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.